February 6, 2014 | Israeli company Tiltan Pharma, which is developing a treatment for pancreatic cancer, has raised $1.5 million. The company will use the proceeds to complete its Phase II clinical trial of its metastatic pancreatic cancer treatment TL-118. Details about the source of the investment were not disclosed.
Related posts
Israeli AI Safety Tool Among TIME’S Best Inventions For 2024
October 31, 2024
TAU Team Discovers Mechanism To Eliminate Cancerous Tumors
October 30, 2024
Ashdod Port Investing In Startups As Part Of Innovation Strategy
October 29, 2024
BGU Develops Fast Fact Checking Via News Sources Not People
October 28, 2024
Facebook comments